$23.14
+0.00 (+0.00%)
Open$23.34
Previous Close$23.14
Day High$23.59
Day Low$22.65
52W High$29.75
52W Low$11.51
Volume—
Avg Volume689.3K
Market Cap1.69B
P/E Ratio—
EPS$-1.37
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
-22.8% upside
Current
$23.14
$23.14
Target
$17.86
$17.86
$12.55
$17.86 avg
$20.90
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 103.79M | 163.26M | 182.20M |
| Net Income | -79,458,304 | -112,494,059 | 28.41M |
| Profit Margin | -76.6% | -72.7% | 15.6% |
| EBITDA | -87,050,379 | -130,089,444 | 52.86M |
| Free Cash Flow | — | — | 21.80M |
| Rev Growth | -36.4% | -36.4% | +8.1% |
| Debt/Equity | — | — | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |